Genprex (GNPX) Stock Receives Validation From NNW

Genprex GNPX Stock News

Genprex Inc (NASDAQ: GNPX) is likely to see gains in the market today after the company received validation from NNW. The stock is already up just under 1%, and the gains are likely just beginning. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GNPX Stock Receives Validation From NetworkNewsWire

In a press release issued early this morning, NetworkNewsWire announced that it published an editorial surrounding Genprex. NetworkNewsWire is a multifaceted financial news and pubishing company.

In the release, NetworkNewsWire pointed to the fact that while 10% of clinical drugs ever make it to the market, those that do generate incredible opportunities for investors. Moreover, the firm pointed to the satisfaction of being involved in work that saves lives and improves quality of life for those that battle serious conditions.

The company went on to point to GNPX as one of these companies. In fact, the firm stated that GNPX is experiencing exciting growth and reaching key milestones in the work to discover lifechanging options for patients.

In the full article, linked to from the press release, the company pointed to key milestones like the announcement of positive preclinical findings from MD Anderson Cancer Center, the development of an Oncoprex and immunotherapy clinical trial design, collaborations surrounding branding, and much more.

The Bottom Line

The bottom line here is simple, NetworkNewsWire provided the same view that I’ve been providing for quite some time now. As Genprex continues to execute with regard to the development of Oncoprex. All in all, Oncoprex represents a tremendous opportunity that should not be ignored!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our FREE mailing list below to receive real-time alerts!

Subscribe Today!

* indicates required

CNA Finance, parent company to Alpha Stock News, has been paid to cover Genprex news.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.